
Claims

1. A compound, or a pharmaceutically acceptable salt thereof or a crystalline hydrate thereof or a solvate thereof; wherein the compound is of formula (I):



(I)

wherein,

R_1 is cyano;

R_2 is OR_3;

R_3 is selected from the group consisting of hydrogen, C_{1-20}alkanoyl, aminoC_{1-20}alkanoyl;

R_4 is hydrogen;

R_5 is C_{1-20}alkanoyl, or aminoC_{1-20}alkanoyl;

R_6 is amino;

R_7 is hydrogen;

R_8 is selected from the group consisting of hydrogen, deuterium, and halogen; and

X is $-CH_2-$, or $-CD_2-$.

2. The compound of claim 1, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof, wherein,

R_3 is selected from the group consisting of hydrogen, formyl, acetyl, propionyl, butyryl, *iso*butyryl, valeroyl, pivaloyl, hexanoyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl; and

R_5 is selected from the group consisting of formyl, acetyl, propionyl, butyryl, *iso*butyryl, valeroyl, pivaloyl, hexanoyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl.

3. The compound claim 1, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof thereof, wherein,

R_8 is deuterium.

4. The compound of claim 1, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof, wherein,

R_1 is cyano;

R_2 is OR_3;

R_3 is selected from the group consisting of hydrogen, propionyl, *iso*butyryl, pivaloyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl;

R_4 is hydrogen;

R_5 is selected from the group consisting of propionyl, *iso*butyryl, pivaloyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl;

R_6 is amino;

R_7 is hydrogen;

R_8 is hydrogen, or deuterium; and

X is $-CH_2-$, or $-CD_2-$.

5. The compound of claim 1, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof, wherein,

R_1 is cyano;

R_2 is OR_3;

R_3 is selected from the group consisting of hydrogen, propionyl, *iso*butyryl, pivaloyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl;

R_4 is hydrogen;

R_5 is selected from the group consisting of propionyl, *iso*butyryl, pivaloyl, α-aminoisovaleryl, 2-ethylbutanoyl, and 3,3-dimethylbutanoyl;


R_6 is amino;

R_7 is hydrogen;


R_8 is deuterium; and

X is $-CH_2-$, or $-CD_2-$.


6. A compound, or a pharmaceutically acceptable salt thereof or a crystalline hydrate thereof or a solvate thereof, wherein the compound is selected from the group consisting of:




A50




A52




A55




A57




A70




A72




A75




A77





A80





A82



A118



A119



A120



A121



A122



A126



A128



A129



A130



A131



A132



A138



A139



A140



A141



A142



A146



A148


A149



A150


A151



A152




A158




A159




A160




A161




A162




A166




A168




A169




A170




A171




A172




A180




A181




A182




A183




A184




A185




A186




A190




A193




A194



A195
































A196



A197

7. The compound of claim 6, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof, wherein the compound is selected from the group consisting of:


A50 ,

A52 ,

A70 ,

A72 ,

A75 ,

A77 ,

A119 ,

A120 ,

A121 ,

A126 ,

A130 ,

A131 ,

A132 ,

A139 ,

A140 ,

A141 ,

A146 ,

A149 ,

A150 ,

A151 ,

A152 ,

A159 ,

A160 ,

A161 ,

A170 ,

A171 ,

A172 ,

A180 , and



A196 .

8. A pharmaceutical composition comprising

(a) the compound of any one of claims 1 to 7, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof; and

(b) pharmaceutically acceptable carriers.

9. A use of the compound of any one of claims 1 to 7, or the pharmaceutically acceptable salt thereof or the crystalline hydrate thereof or the solvate thereof, or the pharmaceutical composition of claim 8 for preparing medicaments for treating, preventing, or alleviating virus infection or diseases associated with virus infection;

wherein

the virus is selected from the group consisting of:

(1) coronavirus infecting human;

(2) human respiratory syncytial virus (RSV);

(3) human influenza virus;

(4) flaviviridae virus;

(5) filoviridae virus; and

(6) coronavirus infecting other mammals; or

the virus is selected from the group consisting of:

severe acute respiratory syndrome coronavirus (SARS-CoV), 2019 novel coronavirus (2019-nCoV or SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), Human coronavirus OC43, Human coronvirus 229E, Human coronvirus NL63, and Human coronvirus HKUL;

and,

the diseases associated with virus infection is selected from the group consisting of:

(D1) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human coronavirus infection;

(D2) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human respiratory syncytial virus

(RSV) infection;

(D3) common cold, high-risk symptom infection, respiratory tract infection, pneumonia and the complications thereof caused by human influenza virus infection;

(D6) infection and the complications thereof caused by Zika virus (Zika);

(D7) hemorrhagic fever and the complications thereof caused by Marburg virus (MBV) and Ebola virus (EBV);

(D8) novel coronavirus pneumonia (Corona Virus Disease 2019， COVID-19) caused by SARS-CoV-2 (COVID-19);

(D9) Porcine epidemic diarrhea caused by porcine epidemic diarrhea virus (PEDV); and

(D10) any combination of the above diseases.

10. The use of claim 9, wherein:

the human influenza virus is selected from the group consisting of influenza A virus, influenza B virus and influenza C virus;

the flaviviridae virus is selected from the group consisting of: hepatitis C virus (HCV), dengue virus (DENV), Zika virus (Zika);

the filoviridae virus is selected from the group consisting of Marburg virus (MBV) and Ebola virus (EBV); and

the coronavirus infecting other mammals is porcine epidemic diarrhea virus (PEDV).